Infectious disease
CEF control Peptide Pool (>95% HPLC, advanced)
Product number:
LB01359
€ 151.30 *
Prices excl. VAT plus shipping
costs
Available, delivery time:
1-3 days
sterile and endotoxin free
Delivery Format: The product is supplied freeze dried.
Purity:
>95% HPLC-MS
Caution:
For research use only. Not for use in humans.
1
Description
The CEF peptide pool is a lyophilized mixture of 32 peptides from cytomegalovirus (CMV), Epstein-Barr virus (EBV), and influenza virus. It consists of defined HLA class I-restricted T cell epitopes from these three viruses, and can be used as a positive control to stimulate T cells. The CEF peptide pool is used as a positive control to stimulate T cells. It induces secretion of e.g., IFN-γ, IL-2, and granzyme B from human CD8 T cells.
One unit allows the stimulation of 2,5 x 108 cells.
For more information and application examples, read our blog posts:
"Esophagogastric adenocarcinoma: Tumor-associated antigens, immune responses and HLA-I expression"
"Quality control of peptide pools in personalized cancer therapy"
TechData
| Delivery: | 1-3 days |
| Counterion: | TFA |
| No. Peptides: | 32 peptides |
| Amount/Aliquote: | 15 nmol (approx. 25µg)/peptide for stimulation of 2,5 x 108 cells |
| Solubility: | Dissolve in a minimum amount of pure DMSO (40µl) and dilute with water to the desired concentration. Please pay attention that the final concentration of DMSO must be below 1% (v/v) to avoid toxicity in the biological system. |
| Species: | Human cytomegalovirus (Human herpesvirus 5), Epstein-Barr virus (EBV; Human herpesvirus 4), Influenza virus |
| Application: | T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response |
| Indication: | Infectious disease, Control |
| Purity: | >95% HPLC-MS |
Documents
References
Bosc-Bierne G, Ewald S, Kreuzer OJ, Weller MG. Efficient Quality Control of Peptide Pools by UHPLC and Simultaneous UV and HRMS Detection. Separations. 2024; 11(5):156. https://doi.org/10.3390/separations11050156
Garcia-Marquez MA, Thelen M, Bauer E, et al.: Germline homozygosity and allelic imbalance of HLA-I are common in esophagogastric adenocarcinoma and impair the repertoire of immunogenic peptides. Journal for ImmunoTherapy of Cancer 2024;12:e007268. doi: 10.1136/jitc-2023-007268
Garcia-Marquez MA, Thelen M, Bauer E, et al.: Germline homozygosity and allelic imbalance of HLA-I are common in esophagogastric adenocarcinoma and impair the repertoire of immunogenic peptides. Journal for ImmunoTherapy of Cancer 2024;12:e007268. doi: 10.1136/jitc-2023-007268